IP Library Granted Patent US 7,169,804
Granted Patent B2
US 7,169,804 · App. 10/363,840 · Granted Jan 30, 2007

Antibacterial mutilins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,804
App. No.
10/363,840
Granted
Jan 30, 2007
Kind
B2
Abstract

A compound of formula (I) wherein R and R 2 together with the nitrogen atom to which they are attached form pyrrolidinyl or piperidinyl, R 1 is a group of formula (II) R 3 and R′ 3 are hydrogen, deuterium or halogen, R 4 , R 5 and R 10 are independently of each other hydrogen or alkyl, R 6 , R 7 and R 8 are hydrogen or deuterium; R 9 is amino, alkyl, aryl, heterocyclyl or mercapto; and, if X is oxygen, R 9 is additionally hydrogen; R′ 10 is alkyl, X is sulphur, oxygen, NR 10 , or N+(R′ 10 ) 2 ; Y is sulphur or oxygen, and m is 0, 1 or 2; with the proviso that, when R and R 2 together with the nitrogen atom to which they are attached form piperidinyl, m is O, Y is S and Y is attached in position 3 of said piperidine ring, that group of formula (I) which is attached to the piperidine ring via the residue Y is either in the (S)-configuration or in the (R)-configuration, preferably in the (S) -configuration which is e.g. useful as antimicrobial, antibacterial.

Claims (12)

1. A compound of formula I

wherein

R 3 , R′ 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are hydrogen;

R 1 is

R and R 2 together with the nitrogen atom to which they are attached form pyrrolidirme;

R 9 is alkyl;

X is oxygen

Y is sulphur; and

m is 0 or 1.

2. A compound of claim 1 in the form of a salt, or in the form of a salt end in the form of a solvate, or in the form of a solvate.

3. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and at least one pharmaceutically acceptable carrier or diluent therefor.

4. A pharmaceutical composition of claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA AND THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 062881 FRAME: 0090. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Jun 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064312/0350 →
RELEASE OF SECURITY INTEREST Recorded Mar 3, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH; ZAVANTE THERAPEUTICS, INC.
Reel/Frame 062881/0090 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 20, 2018
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0110 →
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2016
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037455/0436 →
SECURITY INTEREST Recorded Aug 28, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033647/0657 →
CHANGE OF NAME Recorded Aug 11, 2008
From: NABRIVA THERAPEUTICS FORSCHUNGS GMBH
To: NABRIVA THERAPEUTICS AG
Reel/Frame 021371/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2007
From: ASCHER, GERD; BERNER, HEINZ; HILDEBRANDT, JOHANNES
To: NABRIVA THERAPEUTICS FORSCHUNGS GMBH
Reel/Frame 018783/0780 →
Priority Claims (3)
GB 0022439.4 · Sep 13, 2000 · national
GB 0022440.2 · Sep 13, 2000 · national
GB 0024674.4 · Oct 9, 2000 · national
Continuity (1)
Related Publication 20040102482A1 · May 27, 2004